Biogen (NASDAQ:BIIB) Stock Acquired Rep. Maria Elvira Salazar

Key Points

• Rep. Maria Elvira Salazar disclosed buying Biogen shares worth between $50,001 and $100,000 on May 11, held in her UBS IRA account.
• Biogen stock recently traded near $199.59, close to its 52-week high of $205.97, with a market cap of about $29.47 billion.
• The company beat quarterly expectations, reporting $3.57 EPS on $2.48 billion in revenue, and it raised FY2026 guidance to 14.25–15.25 EPS.

Representative Maria Elvira Salazar (Republican-Florida) recently bought shares of Biogen Inc. NASDAQ: BIIB. In a filing disclosed on June 08th, the Representative disclosed that they had bought between $50,001 and $100,000 in Biogen stock on May 11th. The trade occurred in the Representative's "UBS IRA ACCOUNT" account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Brookfield Renewable Partners NYSE: BEP on 5/29/2026.
• Purchased $15,001 - $50,000 in shares of International Business Machines NYSE: IBM on 5/21/2026.
• Purchased $15,001 - $50,000 in shares of Datadog NASDAQ: DDOG on 5/19/2026.
• Purchased $1,001 - $15,000 in shares of Datadog NASDAQ: DDOG on 5/19/2026.
• Purchased $15,001 - $50,000 in shares of Qualcomm NASDAQ: QCOM on 5/13/2026.
• Purchased $1,001 - $15,000 in shares of Qualcomm NASDAQ: QCOM on 5/13/2026.
• Sold $1,001 - $15,000 in shares of Sherwin-Williams NYSE: SHW on 5/12/2026.
• Purchased $1,001 - $15,000 in shares of Biogen NASDAQ: BIIB on 5/12/2026.
• Sold $1,001 - $15,000 in shares of Whirlpool NYSE: WHR on 5/11/2026.
• Purchased $1,001 - $15,000 in shares of Biogen NASDAQ: BIIB on 5/11/2026.

Biogen Price Performance

Shares of Biogen stock traded up $0.49 during trading hours on Wednesday, reaching $199.59. The company's stock had a trading volume of 140,721 shares, compared to its average volume of 1,256,152. The firm has a 50 day moving average price of $187.94 and a 200-day moving average price of $183.85. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The stock has a market cap of $29.47 billion, a P/E ratio of 21.43 and a beta of 0.20. Biogen Inc. has a one year low of $121.05 and a one year high of $205.97.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company had revenue of $2.48 billion for the quarter, compared to analysts' expectations of $2.29 billion. During the same period in the previous year, the firm posted $3.02 earnings per share. The firm's revenue for the quarter was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, analysts predict that Biogen Inc. will post 14.18 EPS for the current year.

Wall Street Analysts Forecast Growth

BIIB has been the topic of several recent analyst reports. Sanford C. Bernstein reduced their target price on shares of Biogen from $201.00 to $200.00 in a research note on Thursday, April 30th. Oppenheimer upped their price target on shares of Biogen from $275.00 to $300.00 and gave the company an "outperform" rating in a report on Thursday, May 14th. Barclays started coverage on shares of Biogen in a research note on Thursday, February 19th. They issued an "equal weight" rating and a $185.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating on shares of Biogen in a research note on Thursday, May 14th. Finally, Guggenheim increased their price target on Biogen from $246.00 to $260.00 and gave the stock a "buy" rating in a report on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $217.26.

Institutional Trading of Biogen

A number of large investors have recently modified their holdings of BIIB. Reflection Asset Management bought a new position in Biogen in the fourth quarter worth approximately $25,000. WPG Advisers LLC lifted its holdings in shares of Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company's stock worth $26,000 after buying an additional 117 shares during the period. Accredited Wealth Management LLC grew its position in shares of Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company's stock worth $28,000 after buying an additional 185 shares in the last quarter. First Horizon Corp purchased a new position in shares of Biogen during the fourth quarter valued at $30,000. Finally, WFA of San Diego LLC bought a new stake in shares of Biogen in the second quarter valued at about $32,000. Hedge funds and other institutional investors own 87.93% of the company's stock.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida's 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida's 27th Congressional District. She won in the general election on November 5, 2024. Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.